From a therapeutic approach, clinical trials of the IGF-1R small molecule inhibitors, Linsitinib and Figitumumab to treat advanced ACC failed to show benefit in progression-free survival or overall survival [47,48]. Here, IGF1R is linked to adrenal cortex carcinoma.